-
Je něco špatně v tomto záznamu ?
The association of a reduced susceptibility to moxifloxacin in causative Clostridium (Clostridioides) difficile strain with the clinical outcome of patients
M. Krutova, V. Capek, E. Nycova, S. Vojackova, M. Balejova, L. Geigerova, R. Tejkalova, L. Havlinova, I. Vagnerova, P. Cermak, L. Ryskova, P. Jezek, D. Zamazalova, D. Vesela, A. Kucharova, D. Nemcova, M. Curdova, O. Nyc, P. Drevinek
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem
NLK
BioMedCentral
od 2012-12-01
BioMedCentral Open Access
od 2012
Directory of Open Access Journals
od 2012
Free Medical Journals
od 2012
PubMed Central
od 2012
Europe PubMed Central
od 2012
ProQuest Central
od 2015-01-01
Open Access Digital Library
od 2012-01-01
Open Access Digital Library
od 2012-01-01
Nursing & Allied Health Database (ProQuest)
od 2015-01-01
Health & Medicine (ProQuest)
od 2015-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2012
Springer Nature OA/Free Journals
od 2012-12-01
- MeSH
- antibakteriální látky terapeutické užití MeSH
- Clostridioides difficile účinky léků MeSH
- feces mikrobiologie MeSH
- infekce spojené se zdravotní péčí MeSH
- klostridiové infekce farmakoterapie mikrobiologie mortalita MeSH
- lidé MeSH
- mikrobiální testy citlivosti MeSH
- moxifloxacin terapeutické užití MeSH
- ribotypizace MeSH
- senioři MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika MeSH
OBJECTIVES: To investigate the relationship between Clostridium (Clostridioides) difficile strain characteristics and C. difficile infection (CDI) outcome. METHODS: Between October and December 2017, 16 hospitals collected epidemiological data according to the European Centre for Disease Prevention and Control (ECDC) surveillance protocol for CDI. C. difficile isolates were characterized by ribotyping, toxin genes detection and antibiotic susceptibility testing to metronidazole, vancomycin and moxifloxacin. RESULTS: The overall mean CDI incidence density was 4.5 [95% CI 3.6-5.3] cases per 10,000 patient-days. From the 433 CDI cases, 330 (76.2%) were healthcare-associated, 52 (12.0%) cases were community-associated or of unknown origin and 51 (11.8%) CDI cases recurrent; a complicated course of CDI was reported in 65 cases (15.0%). Eighty-eight (20.3%) of patients died and 59 of them within 30 days after the CDI diagnosis. From the 379 C. difficile isolates, the most prevalent PCR ribotypes were 001 (n = 127, 33.5%) and 176 (n = 44, 11.6%). A total of 186 (49.1%) isolates showed a reduced susceptibility to moxifloxacin (> 4 mg/L) and 96.4% of them had Thr82Ile in the GyrA. Nineteen isolates revealed reduced susceptibility to metronidazole and two isolates to vancomycin (> 2 mg/L). A fatal outcome was associated with a reduced susceptibility to moxifloxacin, the advanced age of the patients and a complicated course of CDI (p<0.05). No association between ribotype, binary toxin and a reduced susceptibility to moxifloxacin and complicated course or recurrent CDI was found. CONCLUSIONS: A reduced susceptibility to moxifloxacin, in causative C. difficile strains was associated with fatal outcome of the patients, therefore it is an important marker in surveillance of CDI.
Bioinformatics centre 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Clinical Microbiology and Parasitology Hospital Pribram Pribram Czech Republic
Department of Clinical Microbiology Military University Hospital Prague Czech Republic
Department of Clinical Microbiology University Hospital Hradec Kralove Hradec Kralove Czech Republic
Department of Medical Microbiology and Immunology Hospital Liberec Liberec Czech Republic
Department of Medical Microbiology Hospital Bulovka Prague Czech Republic
Department of Medical Microbiology Hospital Ceske Budejovice Ceske Budejovice Czech Republic
Department of Medical Microbiology Hospital Jindrichuv Hradec Jindrichuv Hradec Czech Republic
Department of Medical Microbiology Hospital Tabor Tabor Czech Republic
Department of Medical Microbiology Thomayer's Hospital Prague Czech Republic
Department of Medical Microbiology University Hospital Brno Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026675
- 003
- CZ-PrNML
- 005
- 20211026132713.0
- 007
- ta
- 008
- 211013s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s13756-020-00765-y $2 doi
- 035 __
- $a (PubMed)32605598
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Krutova, Marcela $u Department of Medical Microbiology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic. marcela.krutova@lfmotol.cuni.cz
- 245 14
- $a The association of a reduced susceptibility to moxifloxacin in causative Clostridium (Clostridioides) difficile strain with the clinical outcome of patients / $c M. Krutova, V. Capek, E. Nycova, S. Vojackova, M. Balejova, L. Geigerova, R. Tejkalova, L. Havlinova, I. Vagnerova, P. Cermak, L. Ryskova, P. Jezek, D. Zamazalova, D. Vesela, A. Kucharova, D. Nemcova, M. Curdova, O. Nyc, P. Drevinek
- 520 9_
- $a OBJECTIVES: To investigate the relationship between Clostridium (Clostridioides) difficile strain characteristics and C. difficile infection (CDI) outcome. METHODS: Between October and December 2017, 16 hospitals collected epidemiological data according to the European Centre for Disease Prevention and Control (ECDC) surveillance protocol for CDI. C. difficile isolates were characterized by ribotyping, toxin genes detection and antibiotic susceptibility testing to metronidazole, vancomycin and moxifloxacin. RESULTS: The overall mean CDI incidence density was 4.5 [95% CI 3.6-5.3] cases per 10,000 patient-days. From the 433 CDI cases, 330 (76.2%) were healthcare-associated, 52 (12.0%) cases were community-associated or of unknown origin and 51 (11.8%) CDI cases recurrent; a complicated course of CDI was reported in 65 cases (15.0%). Eighty-eight (20.3%) of patients died and 59 of them within 30 days after the CDI diagnosis. From the 379 C. difficile isolates, the most prevalent PCR ribotypes were 001 (n = 127, 33.5%) and 176 (n = 44, 11.6%). A total of 186 (49.1%) isolates showed a reduced susceptibility to moxifloxacin (> 4 mg/L) and 96.4% of them had Thr82Ile in the GyrA. Nineteen isolates revealed reduced susceptibility to metronidazole and two isolates to vancomycin (> 2 mg/L). A fatal outcome was associated with a reduced susceptibility to moxifloxacin, the advanced age of the patients and a complicated course of CDI (p<0.05). No association between ribotype, binary toxin and a reduced susceptibility to moxifloxacin and complicated course or recurrent CDI was found. CONCLUSIONS: A reduced susceptibility to moxifloxacin, in causative C. difficile strains was associated with fatal outcome of the patients, therefore it is an important marker in surveillance of CDI.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antibakteriální látky $x terapeutické užití $7 D000900
- 650 _2
- $a Clostridioides difficile $x účinky léků $7 D016360
- 650 _2
- $a klostridiové infekce $x farmakoterapie $x mikrobiologie $x mortalita $7 D003015
- 650 _2
- $a infekce spojené se zdravotní péčí $7 D003428
- 650 _2
- $a feces $x mikrobiologie $7 D005243
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 650 _2
- $a moxifloxacin $x terapeutické užití $7 D000077266
- 650 _2
- $a ribotypizace $7 D021521
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Capek, Vaclav $u Bioinformatics centre, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Nycova, Elka $u Department of Medical Microbiology, Hospital Bulovka, Prague, Czech Republic
- 700 1_
- $a Vojackova, Sabina $u Department of Medical Microbiology, University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Balejova, Magda $u Department of Medical Microbiology, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic
- 700 1_
- $a Geigerova, Lenka $u Department of Medical Microbiology, Faculty of Medicine, Charles University and University Hospital Plzen, Plzen, Czech Republic
- 700 1_
- $a Tejkalova, Renata $u Department of Medical Microbiology, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Brno, Czech Republic
- 700 1_
- $a Havlinova, Lenka $u Department of Medical Microbiology and Immunology, Hospital Liberec, Liberec, Czech Republic
- 700 1_
- $a Vagnerova, Iva $u Department of Microbiology, Faculty of Medicine and Dentistry, Palacky University Hospital, Olomouc, Czech Republic
- 700 1_
- $a Cermak, Pavel $u Department of Medical Microbiology, Thomayer's Hospital, Prague, Czech Republic
- 700 1_
- $a Ryskova, Lenka $u Department of Clinical Microbiology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Jezek, Petr $u Department of Clinical Microbiology and Parasitology, Hospital Pribram, Pribram, Czech Republic
- 700 1_
- $a Zamazalova, Dana $u Department of Clinical Microbiology, Hospital Nove Mesto na Morave, Nove Mesto na Morave, Czech Republic
- 700 1_
- $a Vesela, Denisa $u Department of Medical Microbiology, Hospital Jindrichuv Hradec, Jindrichuv Hradec, Czech Republic
- 700 1_
- $a Kucharova, Alice $u Department of Medical Microbiology, Hospital Tabor, Tabor, Czech Republic
- 700 1_
- $a Nemcova, Dana $u Department of Clinical Microbiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Curdova, Martina $u Department of Clinical Microbiology, Military University Hospital, Prague, Czech Republic
- 700 1_
- $a Nyc, Otakar $u Department of Medical Microbiology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Drevinek, Pavel $u Department of Medical Microbiology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic
- 773 0_
- $w MED00207801 $t Antimicrobial resistance and infection control $x 2047-2994 $g Roč. 9, č. 1 (2020), s. 98
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32605598 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026132719 $b ABA008
- 999 __
- $a ok $b bmc $g 1715420 $s 1147182
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 9 $c 1 $d 98 $e 20200630 $i 2047-2994 $m Antimicrobial resistance and infection control $n Antimicrob Resist Infect Control $x MED00207801
- LZP __
- $a Pubmed-20211013
